December 12, 2025. DSM Nutritional Products' order request hits the Federal Register. Proposed, not final. Public comment window: 45 days [1]. The FDA has been staring at sunscreen ingredient applications since the late 1990s. None have cleared [3]. Bemotrizinol is up to 6 percent concentration, UVA and UVB coverage, low skin absorption[5]. The clock starts.
June 9, 2026. Final order published [1]. Bemotrizinol is in.
Seven months from proposal to approval. The first new active ingredient added to the over-the-counter sunscreen monograph in more than 25 years [3].
what broke the freeze
The last new active ingredient cleared the monograph in the late 1990s [2]. No name given in the record, no chemical specified. Just "late 1990s" as the marker. Twenty-six years of nothing after that [3].
Bemotrizinol has been marketed in Europe and many countries around the world for years [4]. Dual-spectrum protection against ultraviolet A and B rays, low levels of absorption through the skin into the body [5]. The data DSM submitted cleared the GRASE threshold: generally recognized as safe and effective [6]. Safe for adults and children six months and older [1].
What changed wasn't the science. It was the process.
The CARES Act, passed in 2020, created a streamlined mechanism for modifying OTC monographs through administrative order instead of the old public rulemaking slog [7]. Bemotrizinol is the first new active ingredient added to any OTC monograph under that process [7].
The lever existed for six years. DSM Nutritional Products was the first to pull it.
210 days
Proposed order: December 12, 2025. Comment period closes: January 26, 2026. Final order: June 9, 2026 [1].
No record in the sources of how many comments the FDA received, what objections were raised, what specific studies the agency reviewed. Just the timeline. 210 days from proposal to approval.
The final order allows bemotrizinol at concentrations up to 6 percent. DSM Nutritional Products can now manufacture products containing it without filing an approved drug application. The monograph is modified. An OTC drug can enter the market if it meets the monograph's permitted active ingredients, uses, and doses.
the MAHA insertion
HHS Secretary Robert F. Kennedy, Jr. issued a statement: bemotrizinol has been "used safely in Europe for decades".
The approval appears in the Make America Healthy Again Strategy Report as evidence of "sunscreen market innovation". A Swiss chemical company's ingredient request becomes a Trump administration talking point. Proof that the system can move, that regulatory logjams can break, that market access expands under the right conditions.
Bemotrizinol didn't unlock because of MAHA. The CARES Act process predates the strategy report by years. But the timing lines up cleanly enough to claim it.
what's still frozen
Bemotrizinol is the first. The monograph lists other active ingredients. No count given in the sources of how many are still pending, how many companies have requests in the pipeline, whether the seven-month window is replicable or a fluke [3].
The FDA finalized this action within seven months of issuing the proposed order [2]. That speed is the story. Whether it's the new baseline or an outlier won't be clear until the next request moves through.
The final order allows bemotrizinol at concentrations up to 6 percent. For adults and children six months and older [1]. DSM Nutritional Products can now manufacture without an approved drug application. The monograph is modified. No timeline given for when the ingredient hits store shelves.
No timeline given for when the ingredient hits store shelves. DSM will need to formulate products, secure manufacturing partners, and navigate retailer distribution channels before consumers see bemotrizinol-labeled sunscreens. The regulatory gate opened in seven months; the commercial rollout operates on a different clock.
